pantoprazole has been researched along with Esophageal Reflux in 244 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pantoprazole magnesium (pantoprazole-Mg) may display extended inhibition of the proton pump with the potential for improved clinical efficacy in gastro-oesophageal reflux disease (GERD)." | 9.19 | Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. ( Moraes-Filho, JP; Pedroso, M; Quigley, EM, 2014) |
| "The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients." | 9.19 | Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. ( Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014) |
| "Children with gastroesophageal reflux disease (GERD) may benefit from gastric acid suppression with proton pump inhibitors such as pantoprazole." | 9.15 | A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. ( Bishop, P; Comer, GM; James, LP; Katz, MH; Kearns, GL; Maguire, MK; Meng, X; O'Gorman, MA; Rath, N; Tammara, B; Ward, RM, 2011) |
| "The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD)." | 9.15 | Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ( Adcock, KG; Comer, GM; Giblin, J; Kierkus, J; Maguire, MK; Meng, X; Rath, N; Sullivan, JE; Tammara, BK; Ward, RM, 2011) |
| "To observe the clinical efficacy of sequential therapy with pantoprazole in patients with gastro esophageal reflux disease (GERD)." | 9.15 | [Efficacy of sequential therapy with pantoprazole in gastro esophageal reflux disease]. ( Guo, Q; Jia, Y; Shen, S; Wang, F; Yang, Y, 2011) |
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 9.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| " The aim of this study was to determine the clinical and pH-metric effect of treatment with pantoprazole 80 mg for 8 weeks in patients with ear, nose, and throat (ENT) manifestations of gastroesophageal reflux disease associated with pathological proximal acid exposure." | 9.14 | Effect of pantoprazole in patients with chronic laryngitis and pharyngitis related to gastroesophageal reflux disease: clinical, proximal, and distal pH monitoring results. ( Ben Mustapha, N; Besbes, G; Bibani, N; Boubaker, J; Filali, A; Kallel, L; Karoui, S; Matri, S; Sahtout, S; Serghini, M; Zouiten, L, 2010) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 9.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "The pharmacokinetic profile of pantoprazole granules was assessed in neonates and preterm infants with gastroesophageal reflux disease (GERD) in a multicenter, randomized, open-label trial." | 9.14 | Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). ( Comer, GM; Maguire, MK; Meng, X; Rath, N; Stewart, DL; Sullivan, SE; Tammara, B; Ward, RM, 2010) |
| "To determine the efficacy of pantoprazole therapy for daytime somnolence, psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep disordered breathing (OSDB) and gastroesophageal reflux disease (GERD)." | 9.13 | Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing. ( Kushner, J; Steward, DL; Surdulescu, V; Suurna, MV; Welge, J, 2008) |
| "To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire." | 9.12 | Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. ( Bishop, PR; Comer, GM; Gremse, D; Soffer, EF; Tolia, V; Tsou, VM, 2006) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 9.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| "To compare the efficacy and tolerability of S-pantoprazole (20 mg once a day) versus racemic pantoprazole (40 mg once a day) in the treatment of gastro-esophageal reflux disease (GERD)." | 9.12 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. ( Erram, SS; Mandora, VP; Pai, NV; Pai, VG; Shinde, JK; Thacker, HP, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 9.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease." | 9.12 | Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007) |
| "The efficacy of pantoprazole as on-demand therapy for the long-term management of patients with mild gastro-oesophageal reflux disease (GORD) has been demonstrated in clinical studies." | 9.12 | Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. ( Bohuschke, M; Gatz, G; Scholten, T; Teutsch, I, 2007) |
| "Five hundred and eighty-two patients with erosive gastro-oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily." | 9.12 | A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. ( Achim, A; Bardhan, KD; Pfaffenberger, B; Riddermann, T, 2007) |
| "Patients with gastro-oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules." | 9.12 | Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. ( Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007) |
| "To compare the efficacy of pantoprazole and esomeprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms." | 9.11 | 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. ( Beil, W; Gatz, G; Gillessen, A; Hole, U; Modlin, IM, 2004) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 9.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 9.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| " pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study." | 9.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "Thirty-six patients with nocturnal gastro-oesophageal reflux disease symptoms received immediate-release omeprazole and pantoprazole in this open-label, randomized-crossover trial." | 9.11 | Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. ( Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 9.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 9.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 9.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| "To compare the effect of pantoprazole and esomeprazole on intra-oesophageal pH and investigate their pharmacokinetics in patients with symptomatic gastro-oesophageal reflux disease (GORD)." | 9.10 | Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. ( Gatz, G; Huber, R; Mascher, H; Müller, P; Pascu, O; Sander, P; Simon, B, 2003) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 9.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux disease who are switched from an oral (p." | 9.09 | Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. ( Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 9.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 9.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD)." | 8.81 | Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. ( Caro, JJ; Salas, M; Ward, A, 2001) |
| "Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations." | 8.80 | Clinical experience with pantoprazole in gastroesophageal reflux disease. ( Avner, DL, 2000) |
| "The current study was undertaken to evaluate the effect of combined therapy of gabapentin and pantoprazole against forestomach and pylorus ligation-induced gastric esophageal reflux disease (GERD) in albino Wistar rats." | 7.96 | Combined therapy of gabapentin with pantoprazole exhibited better protective action against forestomach and pylorus ligation-induced gastric esophageal reflux disease in albino Wistar rats. ( Arya, P; Kaithwas, G, 2020) |
| "Treatment with lycopene evidenced sententious physiological protection when scrutinized for pH, acidity (total and free), volume of gastric juices and esophagitis index." | 7.81 | Effect of lycopene against gastroesophageal reflux disease in experimental animals. ( Gautam, S; Giri, AK; Kaithwas, G; Rawat, JK; Singh, M, 2015) |
| "This case report highlights a very rare adverse drug reaction caused by oral pantoprazole resulting in acute pancreatitis." | 7.78 | Oral pantoprazole-induced acute pancreatitis in an 11-year-old child. ( Das, S; Dey, JK; Ganguly, A; Ghosh, A; Mondal, S; Saha, I, 2012) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 7.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "To evaluate esophageal mucosal defense mechanisms at an epithelial level to establish if pantoprazole treatment can induce ultrastructural healing and improvement in the proliferation activity of the esophageal epithelium in gastroesophageal reflux disease (GERD)." | 7.75 | Esophageal cell proliferation in gastroesophageal reflux disease: clinical-morphological data before and after pantoprazole. ( Calabrese, C; Cenacchi, G; Derenzini, M; Di Febo, G; Gabusi, V; Liguori, G; Treré, D; Vici, M, 2009) |
| "To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms." | 7.73 | Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| " The patient had initiated treatment with oral pantoprazole 40 mg/d for gastroesophageal reflux 2 months prior to admission." | 7.72 | Acute interstitial nephritis due to pantoprazole. ( Ra, A; Tobe, SW, 2004) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 6.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study." | 6.76 | Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. ( Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011) |
| " Both treatments were well tolerated; most adverse events were of mild or moderate severity and unrelated to the study medication, and there were no unexpected safety concerns." | 6.76 | Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial. ( Hein, J, 2011) |
| "In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods." | 6.75 | Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. ( Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J, 2010) |
| "Pantoprazole 40 mg was at least as effective as esomeprazole 40 mg for relieving GERD symptoms." | 6.73 | Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2007) |
| " This study set out to assess whether increasing the dosage of oral esomeprazole and pantoprazole improves acid control in GORD patients, and to compare the pharmacodynamic efficacy of esomeprazole and pantoprazole administered at different dosages." | 6.73 | Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. ( Backlund, A; Eckerwall, G; Fjellman, M; Lind, T; Röhss, K; Wilder-Smith, C, 2008) |
| "Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents." | 6.72 | Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). ( Baker, R; Book, L; Comer, GM; Hammo, AH; Soffer, EF; Tsou, VM; Wang, W, 2006) |
| "Pantoprazole 40 mg was at least as effective as esomeprazole 40 mg for relieving GERD symptoms." | 6.72 | Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2006) |
| "Pantoprazole was also significantly more efficacious in controlling all gastrointestinal symptoms of GERD." | 6.71 | Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. ( Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 6.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "Despite a high prevalence of mild gastroesophageal reflux disease (GERD), few studies investigated efficacy and safety of proton pump inhibitors in this indication." | 6.70 | Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. ( Biedermann, A; Kaspari, S; Mey, J, 2001) |
| "Pantoprazole once daily was superior to nizatidine b." | 6.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 6.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| "Gastro-oesophageal reflux disease (GORD) is associated with a broad array of symptoms that may be typical or atypical of the disease and that may be accompanied by erosive oesophagitis." | 6.44 | The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire. ( Thomson, AB, 2007) |
| "Pantoprazole has an excellent safety record and shows only minor interaction with other drugs." | 6.43 | Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. ( Beglinger, C; Lehmann, FS, 2005) |
| "Treatment with pantoprazole and aprepitant significantly inhibited the gastric secretion, total acidity, and esophagitis index." | 5.40 | Effect of monotherapy and combination therapy of pantoprazole and aprepitant in gastric esophageal reflux disease in albino rats. ( Kaithwas, G; Kumar, A; Kumar, M; Raj, P; Shukla, K, 2014) |
| "The combination of bronchial asthma with pathology of the digestive tract--one of the most frequent, clinically diverse and difficult, which complicates its course." | 5.39 | [Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma]. ( Popadynets', IR, 2013) |
| "Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life." | 5.36 | [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease]. ( Gillessen, A, 2010) |
| "Duodeno-gastro-esophageal reflux (DGER) is considered as an independent risk factor for complicated reflux disease (GERD)." | 5.35 | Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER). ( Adler, G; Ellenrieder, V; Fensterer, H; Gress, TM; Kunsch, S; Linhart, T; Neesse, A; Steinkamp, M, 2009) |
| "Gastrooesophageal reflux disease (GERD) is highly prevalent in the Western world but its true population prevalence is difficult to estimate without a validated instrument to detect it." | 5.33 | Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. ( Ciconelli, R; de Souza Cury, M; Ferrari, AP; Ferraz, MB; Moraes-Filho, JP, 2006) |
| "Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs." | 5.30 | Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. ( Abdel-Rahman, S; Friesen, CA; Gaedigk, A; Kearns, GL; Leeder, JS; Pearce, RE; Shakhnovich, V; Weigel, J, 2019) |
| "Independent of genotype, when normalized to dose per kg total body weight, pantoprazole apparent clearance and apparent volume of distribution were significantly lower (P < ." | 5.27 | Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. ( Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Smith, PB; Wu, H; Zhao, J, 2018) |
| "In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) Lactobacillus paracasei F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months." | 5.20 | Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. ( Campo, SM; Chiodini, P; Coccoli, P; Compare, D; Larussa, T; Luzza, F; Nardone, G; Nazionale, I; Rocco, A; Sgamato, C, 2015) |
| "Pantoprazole magnesium (pantoprazole-Mg) may display extended inhibition of the proton pump with the potential for improved clinical efficacy in gastro-oesophageal reflux disease (GERD)." | 5.19 | Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. ( Moraes-Filho, JP; Pedroso, M; Quigley, EM, 2014) |
| "The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients." | 5.19 | Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. ( Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014) |
| "Overweight/obesity in GORD patients does not appear to affect the antisecretory efficacy of a single dose of rabeprazole and pantoprazole." | 5.17 | On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? ( Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013) |
| "The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD)." | 5.15 | Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ( Adcock, KG; Comer, GM; Giblin, J; Kierkus, J; Maguire, MK; Meng, X; Rath, N; Sullivan, JE; Tammara, BK; Ward, RM, 2011) |
| "To investigate the influence of irritable bowel syndrome (IBS)-like symptoms on treatment outcomes with pantoprazole in gastroesophageal reflux disease (GERD) in a real life setting." | 5.15 | Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. ( Doerfler, H; Heading, RC; Mönnikes, H; Schmitt, H, 2011) |
| "To observe the clinical efficacy of sequential therapy with pantoprazole in patients with gastro esophageal reflux disease (GERD)." | 5.15 | [Efficacy of sequential therapy with pantoprazole in gastro esophageal reflux disease]. ( Guo, Q; Jia, Y; Shen, S; Wang, F; Yang, Y, 2011) |
| "To compare the effects of immediate-release omeprazole and 2 different delayed-release proton pump inhibitors on 24-hour intragastric acidity in gastroesophageal reflux disease patients." | 5.14 | Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. ( Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009) |
| "Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 5.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| " The aim of this study was to determine the clinical and pH-metric effect of treatment with pantoprazole 80 mg for 8 weeks in patients with ear, nose, and throat (ENT) manifestations of gastroesophageal reflux disease associated with pathological proximal acid exposure." | 5.14 | Effect of pantoprazole in patients with chronic laryngitis and pharyngitis related to gastroesophageal reflux disease: clinical, proximal, and distal pH monitoring results. ( Ben Mustapha, N; Besbes, G; Bibani, N; Boubaker, J; Filali, A; Kallel, L; Karoui, S; Matri, S; Sahtout, S; Serghini, M; Zouiten, L, 2010) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 5.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "The objective of this study was to assess the efficacy of pantoprazole in infants with gastroesophageal reflux disease (GERD)." | 5.14 | Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. ( Comer, GM; Hinz, M; Kierkus, J; Kum-Nji, P; Li, H; Maguire, MK; Mahomedy, SH; Winter, H, 2010) |
| "Was made an investigation of the effectiveness of pantoprazole (sanpraz, "SanFarma", India) at gastroesophageal reflux disease (GERD)." | 5.14 | [Pharmacokinetics of the proton pump inhibitors and psychological status in patients as factors that influence the efficiency of treatment of GERD with pantoprazole]. ( Bordin, DS; Firsova, LD; Ianova, OB; Kozhurina, TS; Masharova, AA; Petrakov, AV; Safonova, OV; Sil'vestrova, SIu; Valitova, ER, 2010) |
| "To determine the efficacy of pantoprazole therapy for daytime somnolence, psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep disordered breathing (OSDB) and gastroesophageal reflux disease (GERD)." | 5.13 | Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing. ( Kushner, J; Steward, DL; Surdulescu, V; Suurna, MV; Welge, J, 2008) |
| "To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire." | 5.12 | Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. ( Bishop, PR; Comer, GM; Gremse, D; Soffer, EF; Tolia, V; Tsou, VM, 2006) |
| "We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study." | 5.12 | Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006) |
| "To compare the efficacy and tolerability of S-pantoprazole (20 mg once a day) versus racemic pantoprazole (40 mg once a day) in the treatment of gastro-esophageal reflux disease (GERD)." | 5.12 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. ( Erram, SS; Mandora, VP; Pai, NV; Pai, VG; Shinde, JK; Thacker, HP, 2006) |
| "The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms." | 5.12 | Esomeprazole versus pantoprazole for healing erosive oesophagitis. ( Begić, I; Bozić, D; Gmajnić, R; Jurcić, D; Khaznadar, E; Kondza, G; Mićunović, N; Ostojić, R; Soldo, I; Vcev, A, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 5.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease." | 5.12 | Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007) |
| "The efficacy of pantoprazole as on-demand therapy for the long-term management of patients with mild gastro-oesophageal reflux disease (GORD) has been demonstrated in clinical studies." | 5.12 | Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. ( Bohuschke, M; Gatz, G; Scholten, T; Teutsch, I, 2007) |
| "In this open, multicentre and multinational clinical trial 840 endoscopy-negative gastro-oesophageal reflux disease patients received pantoprazole 20 mg daily for 28 days." | 5.12 | International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. ( Armstrong, D; Bardhan, KD; Berghöfer, P; Gatz, G; Mönnikes, H; Stanghellini, V, 2007) |
| "Five hundred and eighty-two patients with erosive gastro-oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily." | 5.12 | A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. ( Achim, A; Bardhan, KD; Pfaffenberger, B; Riddermann, T, 2007) |
| "Patients with gastro-oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules." | 5.12 | Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. ( Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007) |
| "To compare the efficacy of pantoprazole and esomeprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms." | 5.11 | 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. ( Beil, W; Gatz, G; Gillessen, A; Hole, U; Modlin, IM, 2004) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 5.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 5.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| " pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study." | 5.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "Thirty-six patients with nocturnal gastro-oesophageal reflux disease symptoms received immediate-release omeprazole and pantoprazole in this open-label, randomized-crossover trial." | 5.11 | Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. ( Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005) |
| "To compare safety and efficacy of on-demand pantoprazole 20 mg/40 mg versus placebo in the long-term management of patients with mild gastroesophageal reflux disease (GERD) after heartburn relief." | 5.11 | On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. ( Bohuschke, M; Dekkers, CP; Gatz, G; Körner, T; Scholten, T; Schütze, K, 2005) |
| "Patients with symptoms of gastro-oesophageal reflux disease and endoscopically confirmed erosive oesophagitis at baseline were randomized to receive esomeprazole 40 mg or pantoprazole 40 mg for up to 8 weeks." | 5.11 | Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. ( Adler, J; Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 5.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| "Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease." | 5.10 | Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. ( Bochenek, W; DeVault, K; Kovacs, TO; Miska, D; Wilcox, CM, 2002) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 5.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "To compare the efficacy and tolerability of pantoprazole 40 mg and omeprazole MUPS 40 mg in patients with moderate to severe gastroesophageal reflux disease (GERD)." | 5.10 | Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. ( Bohuschke, M; Costa Neves, B; Fumagalli, I; Gatz, G; Körner, T; Schütze, K; van Leendert, RJ, 2003) |
| " Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8." | 5.10 | Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. ( Eherer, AJ; Friedrich, G; Habermann, W; Hammer, HF; Kiesler, K; Krejs, GJ, 2003) |
| "To compare the effect of pantoprazole and esomeprazole on intra-oesophageal pH and investigate their pharmacokinetics in patients with symptomatic gastro-oesophageal reflux disease (GORD)." | 5.10 | Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. ( Gatz, G; Huber, R; Mascher, H; Müller, P; Pascu, O; Sander, P; Simon, B, 2003) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 5.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "To compare the efficacy of pantoprazole and esomeprazole for the treatment of gastro-oesophageal reflux disease- (GERD-) related symptoms." | 5.10 | Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. ( Gatz, G; Hole, U; Scholten, T, 2003) |
| "This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylori-negative patients aged 18-60 yr with symptoms of gastroesophageal reflux disease." | 5.10 | Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. ( Chen, Y; Katz, PO; Miner, P; Sostek, M, 2003) |
| "The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux disease who are switched from an oral (p." | 5.09 | Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. ( Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000) |
| "The aim of this study was to compare the efficacy and tolerability of low dose pantoprazole (20 mg) (a gastric proton pump inhibitor) with standard dose ranitidine (300 mg) (a histamine-receptor antagonist), in their ability to relieve symptoms and heal oesophageal lesions associated with gastrooesophageal reflux disease (GORD)." | 5.09 | Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. ( Bethke, T; de K Grundling, H; Fischer, R; O'Keefe, SJ; Retief, FJ; Theron, I; van Rensburg, CJ; van Zyl, JH, 2000) |
| "To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)." | 5.09 | Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000) |
| "The aim of this dose-response study was to compare the effectiveness of 10 mg, 20 mg, and 40 mg of pantoprazole with that of placebo tablets in the healing and symptom relief of gastroesophageal reflux disease associated with erosive esophagitis, and to determine the optimal dose." | 5.09 | Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. ( Bochenek, W; Richter, JE, 2000) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 5.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
| " PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease." | 4.95 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations." | 4.80 | Clinical experience with pantoprazole in gastroesophageal reflux disease. ( Avner, DL, 2000) |
| "The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease." | 4.79 | Clinical efficacy of pantoprazole compared with ranitidine. ( Bader, JP; Delchier, JC, 1994) |
| "The current study was undertaken to evaluate the effect of combined therapy of gabapentin and pantoprazole against forestomach and pylorus ligation-induced gastric esophageal reflux disease (GERD) in albino Wistar rats." | 3.96 | Combined therapy of gabapentin with pantoprazole exhibited better protective action against forestomach and pylorus ligation-induced gastric esophageal reflux disease in albino Wistar rats. ( Arya, P; Kaithwas, G, 2020) |
| "All NCCP patients underwent impedance-pH monitoring and on the basis of the results, those with abnormal distal esophageal acid exposure received PPIs twice daily (group A), those with a positive symptom index for chest pain received citalopram 20 mg and PPI once daily (group B), and those with a negative symptom index for chest pain received citalopram 20 mg once daily (group C)." | 3.85 | Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain. ( Christidou, A; Denaxas, K; Galanopoulos, M; Kamberoglou, D; Karamanolis, DG; Karamanolis, G; Katopodi, K; Mantzaris, GJ; Papatheodoridis, G; Tsoukali, E; Varytimiadis, L; Viazis, N, 2017) |
| "Treatment with lycopene evidenced sententious physiological protection when scrutinized for pH, acidity (total and free), volume of gastric juices and esophagitis index." | 3.81 | Effect of lycopene against gastroesophageal reflux disease in experimental animals. ( Gautam, S; Giri, AK; Kaithwas, G; Rawat, JK; Singh, M, 2015) |
| "Patients with heartburn and negative endoscopy were treated with esomeprazole or pantoprazole 40 mg daily for 8 weeks." | 3.80 | Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. ( Antonelli, A; Bellini, M; de Bortoli, N; Frazzoni, M; Marchi, S; Martinucci, I; Piaggi, P; Savarino, E; Savarino, V, 2014) |
| " A significant reduction in chest pain after pantoprazole therapy (P=." | 3.80 | [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?]. ( Aliaga, V; Domenech, G; Huamán, JW; Saperas, E; Videla, S, 2014) |
| "This case report highlights a very rare adverse drug reaction caused by oral pantoprazole resulting in acute pancreatitis." | 3.78 | Oral pantoprazole-induced acute pancreatitis in an 11-year-old child. ( Das, S; Dey, JK; Ganguly, A; Ghosh, A; Mondal, S; Saha, I, 2012) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 3.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "We aimed to investigate effects of the proton pump inhibitors (PPIs) omeprazole, lansoprazole and pantoprazole, which are currently used for the treatment of hyperacidity and gastro-oesophageal reflux, on the reactivity of the isolated rat lower oesophageal sphincter." | 3.77 | Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter. ( Buyukafsar, K; Erenmemisoglu, A; Ozkur, M; Pektas, M; Un, I; Yurtsever, AS, 2011) |
| "To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms." | 3.73 | Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| " Eight days before admission she had started and continued to take pantoprazole because of symptoms of gastroesophageal reflux." | 3.72 | [Pantoprazole-induced hepatitis]. ( Cordes, A; Maier, KP; Vogt, W, 2003) |
| " The patient had initiated treatment with oral pantoprazole 40 mg/d for gastroesophageal reflux 2 months prior to admission." | 3.72 | Acute interstitial nephritis due to pantoprazole. ( Ra, A; Tobe, SW, 2004) |
| "The results of treatment of duodenal ulcers and gastroesophageal reflux disease with using of modern proton pump inhibitor controloc (pantoprazole) are presented in this article." | 3.72 | [Efficacy of controloc in the treatment of acid-dependent diseases]. ( Agibalov, AN; Chubenko, SS; Gaĭdukov, VO; Onishenko, AV, 2003) |
| " After 3-month treatment with Pantoprazole, a statistically significant improvement was noted for daytime sleepiness (P = ." | 3.72 | Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing. ( Steward, DL, 2004) |
| "Gastro-oesophageal reflux (GOR) is characterised by the regurgitation of gastric contents into the oesophagus." | 3.01 | Pharmacological treatment of gastro-oesophageal reflux in children. ( Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP, 2023) |
| "Gastroesophageal reflux disease (GERD) is a common disease with various clinical presentations." | 2.94 | A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial. ( Anbardar, MH; Bagheri Lankarani, K; Ejtehadi, F; Moini, M; Naini, MA; Nejati, M; Niknam, R; Peymani, P; Sivandzadeh, GR; Taghavi, AR; Zare, M, 2020) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 2.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "Asian patients with GERD symptoms (N = 209) received pantoprazole 40 mg daily for 8 weeks in a multinational, prospective, open-label study." | 2.79 | Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients. ( Choi, KD; Choi, MG; Goh, KL; Hsieh, TY; Jung, HY; Lien, HC; Menon, J; Mesenas, S; Park, H; Sheu, BS; Wu, JC, 2014) |
| "GORD patients who after long-term continuous treatment were able to use less than a daily PPI dose in a placebo-controlled trial were compared to patients who persisted in a daily dosage with respect to general, lifestyle and quality of life characteristics (SF-36 Health Survey) as well as psychological factors (Symptom Check List 90), symptom control on daily PPI (Quality of Life in Reflux and Dyspepsia questionnaire), disease and medication history." | 2.78 | Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error. ( de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2013) |
| "Gastro-oesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are highly prevalent gastrointestinal conditions with accumulating evidence of overlap in patients." | 2.77 | Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. ( Lühmann, R; Mönnikes, H; Sander, P; Schwan, T; Straszak, A; Theek, C; van Rensburg, C, 2012) |
| "To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study." | 2.76 | Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. ( Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011) |
| "Management of patients with gastro-oesophageal reflux disease (GORD) can be assisted by information predicting the likely response to proton pump inhibitor (PPI) treatment." | 2.76 | Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. ( Heading, RC; Mönnikes, H; Schmitt, H; Tholen, A, 2011) |
| "Gastroesophageal reflux is frequently associated with sleep-related breathing disorders." | 2.76 | Proton-pump inhibitors in sleep-related breathing disorders: clinical response and predictive factors. ( Esteller, E; Mearin, F; Modolell, I; Segarra, F, 2011) |
| " Both treatments were well tolerated; most adverse events were of mild or moderate severity and unrelated to the study medication, and there were no unexpected safety concerns." | 2.76 | Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial. ( Hein, J, 2011) |
| "To quantify the effect of blinded dosage reduction after long-term therapy on symptom control and quality of life while assessing pharmacological and placebo needs." | 2.75 | Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. ( de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2010) |
| "In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods." | 2.75 | Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. ( Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J, 2010) |
| "A daily eDiary captured 5 individual GERD symptoms." | 2.75 | Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. ( Baker, R; Baker, SS; Comer, GM; Li, H; Maguire, MK; Rath, N; Tsou, VM; Tung, J; Wang, W, 2010) |
| "A prime concern for gastroesophageal reflux disease (GERD) patients is fast symptom control." | 2.73 | Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. ( Bardhan, KD; Gatz, G; Hein, J; Mönnikes, H; Pfaffenberger, B, 2007) |
| "Pantoprazole 40 mg was at least as effective as esomeprazole 40 mg for relieving GERD symptoms." | 2.73 | Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2007) |
| " This study set out to assess whether increasing the dosage of oral esomeprazole and pantoprazole improves acid control in GORD patients, and to compare the pharmacodynamic efficacy of esomeprazole and pantoprazole administered at different dosages." | 2.73 | Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. ( Backlund, A; Eckerwall, G; Fjellman, M; Lind, T; Röhss, K; Wilder-Smith, C, 2008) |
| "Comparative studies of proton pump inhibitors (PPIs) have revealed that acid reflux is influenced by PPI treatment, formulations and dosing regimens." | 2.73 | Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. ( Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G, 2008) |
| "The cause and effect between gastroesophageal reflux and laryngeal symptoms remain elusive." | 2.72 | Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. ( Harrell, SP; Koopman, J; Lentsch, E; Parker, K; Winstead, W; Wo, JM, 2006) |
| "Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents." | 2.72 | Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). ( Baker, R; Book, L; Comer, GM; Hammo, AH; Soffer, EF; Tsou, VM; Wang, W, 2006) |
| "Pantoprazole 40 mg was at least as effective as esomeprazole 40 mg for relieving GERD symptoms." | 2.72 | Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2006) |
| "Although the diagnosis of gastroesophageal reflux disease (GERD) is based primarily on symptoms experienced by a patient, relatively little attention has been paid to the development and validation of self-administered questionnaires specific to GERD symptoms." | 2.71 | Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. ( Armstrong, D; Goeree, R; Meyer, F; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "Pantoprazole was also significantly more efficacious in controlling all gastrointestinal symptoms of GERD." | 2.71 | Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. ( Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 2.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "A prime concern for gastroesophageal reflux disease (GERD) patients is fast symptom control." | 2.71 | Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. ( Bardhan, KD; Gatz, G; Hein, J; Mönnikes, H; Pfaffenberger, B, 2005) |
| "Pharyngoesophageal gastric acid reflux is thought to initiate chronic posterior laryngitis." | 2.70 | Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux. ( Eherer, A; Friedrich, G; Habermann, W; Kiesler, K, 2002) |
| "Despite a high prevalence of mild gastroesophageal reflux disease (GERD), few studies investigated efficacy and safety of proton pump inhibitors in this indication." | 2.70 | Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. ( Biedermann, A; Kaspari, S; Mey, J, 2001) |
| "Pantoprazole once daily was superior to nizatidine b." | 2.70 | Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001) |
| "Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+." | 2.68 | One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997) |
| "PPIs are not effective in reducing GERD symptoms in infants." | 2.47 | Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. ( Benninga, MA; Omari, TI; Smits, MJ; Tabbers, MM; van der Pol, RJ; van Wijk, MP, 2011) |
| "Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion." | 2.45 | Pantoprazole: a proton pump inhibitor. ( Moreira Dias, L, 2009) |
| "Pantoprazole has an excellent safety profile and a low potential for drug-drug interactions." | 2.44 | Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. ( Devault, KR, 2007) |
| "Gastro-oesophageal reflux disease (GORD) is associated with a broad array of symptoms that may be typical or atypical of the disease and that may be accompanied by erosive oesophagitis." | 2.44 | The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire. ( Thomson, AB, 2007) |
| "The prevalence of gastroesophageal reflux disease (GERD) increases with age and elderly are more likely to develop severe disease." | 2.44 | Long-term management of GERD in the elderly with pantoprazole. ( Calabrese, C; Di Febo, G; Fabbri, A, 2007) |
| "Pantoprazole has been assessed in most of the clinical situations where acid suppression is required, and showed great efficacy and an excellent safety profile." | 2.44 | Pantoprazole: from drug metabolism to clinical relevance. ( Bardou, M; Martin, J, 2008) |
| "Esomeprazole has been shown to be more effective than lansoprazole in relieving GORD symptoms, and esomeprazole and pantoprazole appear to be equally effective in resolving GORD symptoms in a comparative study." | 2.43 | Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. ( Orr, WC, 2005) |
| "Pantoprazole has an excellent safety record and shows only minor interaction with other drugs." | 2.43 | Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. ( Beglinger, C; Lehmann, FS, 2005) |
| "Gastroesophageal reflux disease (GERD) is a highly prevalent disorder which affects 10-30% of the population in Western countries." | 2.43 | Understanding GERD symptoms in the clinical setting. ( Holtmann, G, 2005) |
| "Extraesophageal manifestations of gastroesophageal reflux disease (GERD) can include upper airway disorders, asthma and chronic cough." | 2.43 | Extraesophageal manifestations of GERD: diagnosis and therapy. ( Halstead, LA, 2005) |
| "The presence of esophageal lesions and gastroesophageal reflux disease (GERD) symptoms do not coincide in some patients: some individuals suffer from the symptoms of GERD but have no evidence of GERD at endoscopy; while conversely, some with endoscopic evidence of GERD do not experience symptoms." | 2.43 | The complete remission concept. ( Mönnikes, H, 2006) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| "Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus." | 2.42 | [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease]. ( Balashova, NN; Busarova, GA; Maev, IV, 2003) |
| " Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal." | 2.41 | The clinical importance of proton pump inhibitor pharmacokinetics. ( Thomson, AB; Yacyshyn, BR, 2002) |
| "Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population." | 2.41 | The pharmacology and clinical relevance of proton pump inhibitors. ( Frissora, C; Katz, PO, 2002) |
| "Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| " Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other." | 2.41 | Switching between intravenous and oral pantoprazole. ( Pisegna, JR, 2001) |
| "Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K(+)-ATPase) inhibitor." | 2.41 | Pantoprazole. ( Poole, P, 2001) |
| " The time of dosing and ingestion of meals may also influence the pharmacokinetics of these agents as well as their ability to suppress gastric acid secretion." | 2.41 | Shortcomings of the first-generation proton pump inhibitors. ( Tytgat, GN, 2001) |
| "Gastroesophageal reflux disease results from excessive exposure of the oesophagus to acidic contents." | 2.40 | Acid pump inhibitors. The treatment of gastroesophageal reflux. ( Hetzel, D, 1998) |
| "Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion." | 2.39 | Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. ( Fitton, A; Wiseman, L, 1996) |
| " The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs." | 2.39 | Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. ( Berstad, A; Hatlebakk, JG, 1996) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "Combination therapy for GERD is preferred in patients with EE." | 1.72 | [Esophagoprotective therapy in patients with erosive esophagitis]. ( Bakulina, NV; Ilchishina, TA; Tikhonov, SV; Topalova, YG; Vasiliev, RV, 2022) |
| " Further studies are warranted to optimize dosage and duration of the intervention." | 1.56 | The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. ( Blesl, A; Feldbacher, N; Horvath, A; Komarova, I; Leber, B; Rainer, F; Stadlbauer, V; Steinwender, M, 2020) |
| "Pantoprazole (5 mg/kg) was administered intraperitoneally to the PPI and PPI+R groups." | 1.48 | Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. ( Choi, YK; Chung, JW; Gweon, TG; Kim, BW; Kim, CW; Kim, HG; Kim, JS; Park, JH; Park, SM, 2018) |
| "Gastroesophageal reflux is an important pathogenic factor to the VPG." | 1.42 | [Diagnosis and treatment of vocal process granuloma induced by gastroesophageal reflux: four cases report]. ( Chen, L; Hong, Y; Li, Z; Shen, W; Xu, H, 2015) |
| "Treatment with pantoprazole and aprepitant significantly inhibited the gastric secretion, total acidity, and esophagitis index." | 1.40 | Effect of monotherapy and combination therapy of pantoprazole and aprepitant in gastric esophageal reflux disease in albino rats. ( Kaithwas, G; Kumar, A; Kumar, M; Raj, P; Shukla, K, 2014) |
| "Despite GERD being a chronic disease in most patients, there was a high degree of alteration seen in the utilization patterns of PPIs." | 1.39 | Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. ( Hatlebakk, JG; Jonasson, C; Tvete, IF, 2013) |
| "The combination of bronchial asthma with pathology of the digestive tract--one of the most frequent, clinically diverse and difficult, which complicates its course." | 1.39 | [Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma]. ( Popadynets', IR, 2013) |
| "In our study of 154 GERD patients, 50 received omeprazole, 51 - lansoprazole and 53 - pantoprazole in a standard daily dose." | 1.38 | [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors]. ( , 2012) |
| "Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief." | 1.38 | Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. ( Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B, 2012) |
| "Treatment with pantoprazole resulted in a significant reduction of acidic reflux in both PPI responders and PPI nonresponders." | 1.38 | Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. ( Ellenrieder, V; Gress, TM; Kunsch, S; Linhart, T; Neesse, A; Nell, C, 2012) |
| " Pantoprazole pharmacokinetic parameters appear to be similar in pediatric patients compared to adults when allometrically scaled." | 1.37 | Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. ( Comer, G; Gastonguay, MR; Knebel, W; Meng, X; Tammara, B; Udata, C, 2011) |
| " However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| "Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life." | 1.36 | [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease]. ( Gillessen, A, 2010) |
| "Although erosive gastro-oesophageal reflux disease (GERD) is a highly prevalent condition, there is no specific, valid, reliable and sensitive questionnaire that allows evaluating treatment-induced changes in health-related quality of life (HRQoL)." | 1.35 | International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease. ( Chassany, O; Devault, KR; Doerfler, H; Gebauer, U; Holtmann, G; Malagelada, JR; Schmitt, H, 2009) |
| "Duodeno-gastro-esophageal reflux (DGER) is considered as an independent risk factor for complicated reflux disease (GERD)." | 1.35 | Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER). ( Adler, G; Ellenrieder, V; Fensterer, H; Gress, TM; Kunsch, S; Linhart, T; Neesse, A; Steinkamp, M, 2009) |
| " The literature suggests three possibilities to explain the inadequacy of the substitution: (a) biphasic metabolism where the raised pH in the stomach may prematurely inactivate the PPI, with an unpredictable effect, (b) differences in acid-resistant coating of the generic products, and (c) influence of multiple dosing of PPIs after several days' use." | 1.35 | [Why some proton pump inhibitors are more equal than others]. ( Lekkerkerker, JF; Mulder, CJ; Otten, MH, 2009) |
| "Gastro-oesophageal reflux is the third most frequent cause of chronic cough." | 1.35 | Chronic cough--about a clinical case... ( Fonseca, G, 2009) |
| "In 20 GERD patients with normal esophageal peristalsis an NF was performed, in 20 patients with impaired esophageal peristalsis a PPF was chosen, and 20 patients received proton-pump inhibitor (PPI) treatment." | 1.35 | Laparoscopic partial posterior (Toupet) fundoplication improves esophageal bolus propagation on scintigraphy. ( Bodner, J; Bonatti, H; Gadenstaetter, M; Hugl, B; Wetscher, GJ; Wykypiel, H, 2008) |
| "Patients with cerebral palsy are known to have a higher incidence of GORD as well as problems with swallowing, vomiting and recurrent chest infections." | 1.35 | Oral impact of gastro-oesophageal reflux disease: a case report. ( Liberali, S, 2008) |
| "The changes in gastroesophageal reflux disease (GERD)-related symptoms on treatment are variously described, but currently available questionnaires have shortcomings." | 1.34 | Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. ( Armstrong, D; Bardhan, KD; Berghöfer, P; Gatz, G; Mönnikes, H; Stanghellini, V, 2007) |
| "Evaluation of the response of gastroesophageal reflux disease (GERD) symptoms to treatment would be facilitated by a brief, valid, reliable and responsive, self-assessed GERD-sensitive scale." | 1.34 | Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. ( Armstrong, D; Bardhan, KD; Berghöfer, P; Bethke, TD; Mönnikes, H; Stanghellini, V, 2007) |
| " Long-term dosing schedule (high dose or step-down dose) was based on current market data." | 1.33 | Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. ( Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005) |
| " Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy." | 1.33 | Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. ( Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006) |
| "Gastrooesophageal reflux disease (GERD) is highly prevalent in the Western world but its true population prevalence is difficult to estimate without a validated instrument to detect it." | 1.33 | Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. ( Ciconelli, R; de Souza Cury, M; Ferrari, AP; Ferraz, MB; Moraes-Filho, JP, 2006) |
| "Gastroesophageal reflux disease (GERD) has evolved from a scarcely reported, little understood disease process just a century ago to a now highly prevalent disease with up to 25% of the population complaining of symptoms of reflux." | 1.32 | GERD 2003: issues from the past and a consensus for the future. ( Kidd, M; Modlin, I, 2004) |
| "Gastroesophageal reflux disease has a multifactorial etiology." | 1.31 | Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. ( Gadenstaetter, M; Klaus, A; Klingler, PJ; Obrist, P; Profanter, C; Weiss, H; Wetscher, GJ; Wykypiel, H, 2001) |
| "Gastroesophageal reflux (GER) is associated with a variety of laryngopharyngeal signs and symptoms." | 1.31 | Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux. ( Fuleihan, N; Hamdan, AL; Sharara, AI; Younes, A, 2001) |
| "Only surgery improved regurgitation." | 1.30 | The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (4.51) | 18.2507 |
| 2000's | 157 (64.34) | 29.6817 |
| 2010's | 69 (28.28) | 24.3611 |
| 2020's | 7 (2.87) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 3 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 2 |
| Bakulina, NV | 1 |
| Tikhonov, SV | 1 |
| Topalova, YG | 1 |
| Ilchishina, TA | 1 |
| Vasiliev, RV | 1 |
| Tighe, MP | 1 |
| Andrews, E | 1 |
| Liddicoat, I | 1 |
| Afzal, NA | 1 |
| Hayen, A | 1 |
| Beattie, RM | 1 |
| Steurer, J | 1 |
| Arya, P | 1 |
| Kaithwas, G | 3 |
| Horvath, A | 1 |
| Leber, B | 1 |
| Feldbacher, N | 1 |
| Steinwender, M | 1 |
| Komarova, I | 1 |
| Rainer, F | 1 |
| Blesl, A | 1 |
| Stadlbauer, V | 1 |
| Bagheri Lankarani, K | 1 |
| Sivandzadeh, GR | 1 |
| Zare, M | 1 |
| Nejati, M | 1 |
| Niknam, R | 1 |
| Taghavi, AR | 1 |
| Ejtehadi, F | 1 |
| Naini, MA | 1 |
| Moini, M | 1 |
| Anbardar, MH | 1 |
| Peymani, P | 1 |
| Cho, JH | 1 |
| Yoon, H | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Viazis, N | 1 |
| Katopodi, K | 1 |
| Karamanolis, G | 1 |
| Denaxas, K | 1 |
| Varytimiadis, L | 1 |
| Galanopoulos, M | 1 |
| Tsoukali, E | 1 |
| Kamberoglou, D | 1 |
| Christidou, A | 1 |
| Karamanolis, DG | 1 |
| Papatheodoridis, G | 1 |
| Mantzaris, GJ | 1 |
| Gweon, TG | 1 |
| Park, JH | 1 |
| Kim, BW | 1 |
| Choi, YK | 1 |
| Kim, JS | 1 |
| Park, SM | 1 |
| Kim, CW | 1 |
| Kim, HG | 1 |
| Chung, JW | 1 |
| Shakhnovich, V | 2 |
| Smith, PB | 1 |
| Guptill, JT | 1 |
| James, LP | 2 |
| Collier, DN | 1 |
| Wu, H | 1 |
| Livingston, CE | 1 |
| Zhao, J | 1 |
| Kearns, GL | 3 |
| Lu, B | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Wang, B | 1 |
| Zou, X | 1 |
| Fei, G | 1 |
| Chen, D | 1 |
| Wang, X | 1 |
| Wu, B | 1 |
| Zou, D | 2 |
| Schmitz, B | 1 |
| Sorrells, T | 1 |
| Glass, JS | 1 |
| Abdel-Rahman, S | 1 |
| Friesen, CA | 1 |
| Weigel, J | 1 |
| Pearce, RE | 1 |
| Gaedigk, A | 1 |
| Leeder, JS | 1 |
| Jonasson, C | 1 |
| Tvete, IF | 1 |
| Hatlebakk, JG | 2 |
| Bruley des Varannes, S | 1 |
| Coudsy, B | 1 |
| Waechter, S | 1 |
| Delemos, B | 3 |
| Xiang, J | 2 |
| Lococo, J | 2 |
| Ducrotté, P | 1 |
| Mönnikes, H | 10 |
| Schwan, T | 3 |
| van Rensburg, C | 3 |
| Straszak, A | 2 |
| Theek, C | 2 |
| Lühmann, R | 4 |
| Sander, P | 4 |
| Tholen, A | 2 |
| Moraes-Filho, JP | 3 |
| Pedroso, M | 2 |
| Quigley, EM | 2 |
| Dhaliwal, A | 1 |
| Nwokolo, C | 1 |
| Remes-Troche, JM | 1 |
| Sobrino-Cossío, S | 1 |
| Soto-Pérez, JC | 1 |
| Teramoto-Matsubara, O | 1 |
| Morales-Arámbula, M | 1 |
| Orozco-Gamiz, A | 1 |
| Tamayo de la Cuesta, JL | 1 |
| Mateos, G | 1 |
| Martinucci, I | 1 |
| de Bortoli, N | 1 |
| Savarino, E | 1 |
| Piaggi, P | 1 |
| Bellini, M | 1 |
| Antonelli, A | 1 |
| Savarino, V | 2 |
| Frazzoni, M | 2 |
| Marchi, S | 1 |
| Schmutz, JL | 1 |
| Trechot, P | 1 |
| Inci, F | 1 |
| Atmaca, M | 1 |
| Ozturk, M | 1 |
| Yildiz, S | 1 |
| Koceroglu, R | 1 |
| Sekeroglu, R | 1 |
| Ipekci, SH | 1 |
| Kebapcilar, L | 1 |
| Huamán, JW | 1 |
| Aliaga, V | 1 |
| Domenech, G | 1 |
| Videla, S | 1 |
| Saperas, E | 1 |
| Becker, V | 1 |
| Grotz, S | 1 |
| Schlag, C | 1 |
| Nennstiel, S | 1 |
| Beitz, A | 1 |
| Haller, B | 1 |
| Schmid, RM | 1 |
| Meining, A | 1 |
| Bajbouj, M | 1 |
| Shukla, K | 1 |
| Raj, P | 1 |
| Kumar, A | 1 |
| Kumar, M | 1 |
| Goh, KL | 3 |
| Choi, KD | 1 |
| Choi, MG | 1 |
| Hsieh, TY | 1 |
| Jung, HY | 1 |
| Lien, HC | 1 |
| Menon, J | 1 |
| Mesenas, S | 1 |
| Park, H | 1 |
| Sheu, BS | 2 |
| Wu, JC | 1 |
| Popadynets', IR | 1 |
| Compare, D | 1 |
| Rocco, A | 1 |
| Sgamato, C | 1 |
| Coccoli, P | 1 |
| Campo, SM | 1 |
| Nazionale, I | 1 |
| Larussa, T | 1 |
| Luzza, F | 1 |
| Chiodini, P | 1 |
| Nardone, G | 1 |
| Giri, AK | 1 |
| Rawat, JK | 1 |
| Singh, M | 1 |
| Gautam, S | 1 |
| Klyaritskaya, IL | 1 |
| Rabotyagova, YS | 1 |
| Steingoetter, A | 1 |
| Sauter, M | 1 |
| Curcic, J | 1 |
| Liu, D | 1 |
| Menne, D | 1 |
| Fried, M | 1 |
| Fox, M | 1 |
| Schwizer, W | 1 |
| Li, Z | 1 |
| Xu, H | 1 |
| Hong, Y | 1 |
| Shen, W | 1 |
| Chen, L | 1 |
| Petryszyn, P | 1 |
| Staniak, A | 1 |
| Grzegrzolka, J | 1 |
| Dunbar, KB | 1 |
| Agoston, AT | 1 |
| Odze, RD | 1 |
| Huo, X | 1 |
| Pham, TH | 1 |
| Cipher, DJ | 1 |
| Castell, DO | 1 |
| Genta, RM | 1 |
| Souza, RF | 1 |
| Çelebi, A | 1 |
| Aydın, D | 1 |
| Kocaman, O | 1 |
| Konduk, BT | 1 |
| Şentürk, Ö | 1 |
| Hülagü, S | 1 |
| Modak, AS | 1 |
| Klyarytska, I | 1 |
| Kriviy, V | 1 |
| Tsapyak, T | 1 |
| Rabotyagova, Y | 1 |
| Suurna, MV | 1 |
| Welge, J | 1 |
| Surdulescu, V | 1 |
| Kushner, J | 1 |
| Steward, DL | 2 |
| Law, JK | 1 |
| Andrews, CN | 1 |
| Enns, R | 1 |
| Ballard, ED | 1 |
| Koch, FK | 1 |
| Gautille, TC | 1 |
| Bagin, RG | 1 |
| Dietrich, CG | 1 |
| Laupichler, S | 1 |
| Stanzel, S | 1 |
| Winograd, R | 1 |
| Al-Taie, O | 1 |
| Gartung, C | 1 |
| Geier, A | 1 |
| Devault, KR | 2 |
| Lazebnik, LB | 1 |
| Vasil'ev, IuV | 1 |
| Antipina, TV | 1 |
| Merkulova, SA | 1 |
| Dobrochasova, NM | 1 |
| Guseva, MV | 1 |
| Tkacheva, AG | 1 |
| Holtmann, G | 3 |
| Chassany, O | 1 |
| Schmitt, H | 3 |
| Gebauer, U | 1 |
| Doerfler, H | 2 |
| Malagelada, JR | 1 |
| Calabrese, C | 4 |
| Treré, D | 1 |
| Liguori, G | 2 |
| Gabusi, V | 2 |
| Vici, M | 1 |
| Cenacchi, G | 1 |
| Derenzini, M | 1 |
| Di Febo, G | 4 |
| Zheng, RN | 1 |
| Kunsch, S | 3 |
| Neesse, A | 2 |
| Linhart, T | 2 |
| Steinkamp, M | 1 |
| Fensterer, H | 2 |
| Adler, G | 2 |
| Gress, TM | 2 |
| Ellenrieder, V | 3 |
| Pellicano, R | 1 |
| Sharova, EP | 1 |
| Kurilovich, SA | 1 |
| Chernosheĭkina, LE | 1 |
| Bucknall, C | 1 |
| Stanton, A | 1 |
| Miller, G | 1 |
| Rajoriya, N | 1 |
| Babu, S | 1 |
| Mackenzie, J | 1 |
| Otten, MH | 1 |
| Lekkerkerker, JF | 1 |
| Mulder, CJ | 1 |
| Chen, WY | 1 |
| Chang, WL | 1 |
| Tsai, YC | 1 |
| Cheng, HC | 1 |
| Lu, CC | 1 |
| Moreira Dias, L | 1 |
| Brigas, D | 1 |
| Gonçalves, AR | 1 |
| Fonseca, G | 1 |
| Karoui, S | 1 |
| Bibani, N | 1 |
| Sahtout, S | 1 |
| Zouiten, L | 1 |
| Kallel, L | 1 |
| Matri, S | 1 |
| Serghini, M | 1 |
| Ben Mustapha, N | 1 |
| Boubaker, J | 1 |
| Besbes, G | 1 |
| Filali, A | 1 |
| van der Velden, AW | 2 |
| de Wit, NJ | 2 |
| Quartero, AO | 2 |
| Grobbee, DE | 2 |
| Numans, ME | 2 |
| Miner, P | 2 |
| Ieni, J | 1 |
| Ward, RM | 3 |
| Tammara, B | 3 |
| Sullivan, SE | 1 |
| Stewart, DL | 2 |
| Rath, N | 6 |
| Meng, X | 4 |
| Maguire, MK | 6 |
| Comer, GM | 9 |
| Winter, H | 1 |
| Kum-Nji, P | 1 |
| Mahomedy, SH | 1 |
| Kierkus, J | 3 |
| Hinz, M | 1 |
| Li, H | 2 |
| Haag, S | 1 |
| Morgan, D | 1 |
| Pandolfino, J | 1 |
| Katz, PO | 5 |
| Goldstein, JL | 1 |
| Barker, PN | 1 |
| Illueca, M | 1 |
| Knebel, W | 1 |
| Udata, C | 1 |
| Comer, G | 1 |
| Gastonguay, MR | 1 |
| Gillessen, A | 5 |
| Baker, R | 2 |
| Tsou, VM | 3 |
| Tung, J | 1 |
| Baker, SS | 1 |
| Wang, W | 4 |
| Kahrilas, PJ | 1 |
| Furmaga-Jablonska, W | 1 |
| Sullivan, JE | 2 |
| David, ES | 1 |
| Fu, C | 1 |
| Bishop, P | 1 |
| O'Gorman, MA | 1 |
| Katz, MH | 1 |
| Orenstein, SR | 1 |
| Hassall, E | 1 |
| Sachs, G | 2 |
| Shin, JM | 2 |
| Hunt, R | 1 |
| Bjornsson, E | 1 |
| Kindt, S | 1 |
| Imschoot, J | 1 |
| Tack, J | 1 |
| Bordin, DS | 1 |
| Masharova, AA | 2 |
| Sil'vestrova, SIu | 1 |
| Firsova, LD | 1 |
| Safonova, OV | 1 |
| Petrakov, AV | 1 |
| Kozhurina, TS | 1 |
| Valitova, ER | 2 |
| Ianova, OB | 2 |
| van der Pol, RJ | 1 |
| Smits, MJ | 1 |
| van Wijk, MP | 1 |
| Omari, TI | 1 |
| Tabbers, MM | 1 |
| Benninga, MA | 1 |
| Heading, RC | 2 |
| Cheong, JH | 1 |
| Kim, GH | 1 |
| Lee, BE | 1 |
| Choi, MK | 1 |
| Moon, JY | 1 |
| Ryu, DY | 1 |
| Kim, DU | 1 |
| Song, GA | 1 |
| Tammara, BK | 1 |
| Adcock, KG | 1 |
| Giblin, J | 1 |
| Modolell, I | 2 |
| Esteller, E | 2 |
| Segarra, F | 2 |
| Mearin, F | 1 |
| Hein, J | 3 |
| Yurtsever, AS | 1 |
| Pektas, M | 1 |
| Ozkur, M | 1 |
| Un, I | 1 |
| Erenmemisoglu, A | 1 |
| Buyukafsar, K | 1 |
| Kim, VA | 1 |
| Zelenkin, SA | 1 |
| Wang, F | 1 |
| Yang, Y | 1 |
| Guo, Q | 1 |
| Jia, Y | 1 |
| Shen, S | 1 |
| Duman, M | 1 |
| Ozer, M | 1 |
| Reyhan, E | 1 |
| Demirci, Y | 1 |
| Atıcı, AE | 1 |
| Dalgıç, T | 1 |
| Bostancı, EB | 1 |
| Genç, E | 1 |
| Das, S | 1 |
| Ganguly, A | 1 |
| Ghosh, A | 1 |
| Mondal, S | 1 |
| Dey, JK | 1 |
| Saha, I | 1 |
| Bytzer, P | 1 |
| van Zanten, SV | 1 |
| Mattsson, H | 1 |
| Wernersson, B | 1 |
| Nell, C | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Armstrong, D | 10 |
| Kazim, F | 1 |
| Gervais, M | 1 |
| Pyzyk, M | 4 |
| Talley, NJ | 1 |
| Moore, MG | 1 |
| Sprogis, A | 1 |
| Katelaris, P | 3 |
| Habermann, W | 3 |
| Kiesler, K | 2 |
| Eherer, A | 2 |
| Friedrich, G | 3 |
| Yacyshyn, BR | 1 |
| Thomson, AB | 3 |
| Frissora, C | 1 |
| Kovacs, TO | 1 |
| Wilcox, CM | 1 |
| DeVault, K | 1 |
| Miska, D | 1 |
| Bochenek, W | 3 |
| Cheer, SM | 1 |
| Prakash, A | 1 |
| Faulds, D | 1 |
| Lamb, HM | 1 |
| Dabney-Smith, K | 1 |
| Nam, J | 1 |
| Ghazale, A | 1 |
| Cai, Q | 1 |
| De Micheli, E | 1 |
| Grisendi, A | 1 |
| Cordes, A | 1 |
| Vogt, W | 1 |
| Maier, KP | 1 |
| Körner, T | 2 |
| Schütze, K | 4 |
| van Leendert, RJ | 1 |
| Fumagalli, I | 2 |
| Costa Neves, B | 1 |
| Bohuschke, M | 3 |
| Gatz, G | 12 |
| van Hout, BA | 1 |
| Klok, RM | 1 |
| Brouwers, JR | 1 |
| Postma, MJ | 1 |
| Paré, P | 3 |
| Meyer, F | 1 |
| Pericak, D | 3 |
| Goeree, R | 1 |
| Eherer, AJ | 1 |
| Hammer, HF | 1 |
| Krejs, GJ | 1 |
| Simon, B | 1 |
| Müller, P | 1 |
| Pascu, O | 1 |
| Huber, R | 1 |
| Mascher, H | 1 |
| Hellström, PM | 1 |
| Vitols, S | 1 |
| Ricciardi, L | 1 |
| Fedele, R | 1 |
| Mazzeo, L | 1 |
| Saitta, S | 1 |
| Mancuso, V | 1 |
| Isola, S | 1 |
| Scholten, T | 3 |
| Hole, U | 2 |
| Wang, YR | 1 |
| Pauly, MV | 1 |
| Lin, YA | 1 |
| Maev, IV | 1 |
| Balashova, NN | 1 |
| Busarova, GA | 1 |
| Barbato, A | 1 |
| Panizzolo, C | 1 |
| Landi, L | 1 |
| Semenzato, R | 1 |
| Rugge, M | 1 |
| Chen, Y | 1 |
| Sostek, M | 1 |
| Ra, A | 1 |
| Tobe, SW | 1 |
| Chubenko, SS | 1 |
| Gaĭdukov, VO | 1 |
| Agibalov, AN | 1 |
| Onishenko, AV | 1 |
| Pehl, C | 1 |
| Boccali, I | 1 |
| Hennig, M | 1 |
| Schepp, W | 1 |
| Beil, W | 1 |
| Modlin, IM | 1 |
| Weber, R | 1 |
| Modlin, I | 1 |
| Kidd, M | 1 |
| Singh, G | 1 |
| van Zyl, J | 1 |
| Vieweg, W | 1 |
| Fischer, R | 2 |
| Richter, JE | 2 |
| Fraga, P | 1 |
| Mack, M | 1 |
| Sabesin, SM | 1 |
| Röhss, K | 2 |
| Lind, T | 2 |
| Wilder-Smith, C | 2 |
| Hill, RK | 1 |
| Simpson, CB | 1 |
| Velazquez, R | 1 |
| Larson, N | 1 |
| Kollmeier, AP | 1 |
| Eddleston, J | 1 |
| Zuraw, BL | 1 |
| Christiansen, SC | 1 |
| Bochenek, WJ | 1 |
| Mack, ME | 1 |
| Fraga, PD | 1 |
| Metz, DC | 3 |
| Madan, K | 1 |
| Ahuja, V | 1 |
| Kashyap, PC | 1 |
| Sharma, MP | 1 |
| Orr, WC | 1 |
| Madisch, A | 1 |
| Kuhlisch, E | 1 |
| Miehlke, S | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Lehmann, FS | 1 |
| Beglinger, C | 1 |
| Labenz, J | 3 |
| Lauritsen, K | 2 |
| Schmidt, S | 2 |
| Wallner, G | 2 |
| Juergens, H | 2 |
| Preiksaitis, H | 2 |
| Keeling, N | 2 |
| Nauclér, E | 2 |
| Eklund, S | 2 |
| Calleja, JL | 1 |
| Suarez, M | 1 |
| De Tejada, AH | 1 |
| Navarro, A | 1 |
| Pfaffenberger, B | 5 |
| Bardhan, KD | 7 |
| Castell, D | 1 |
| Bagin, R | 1 |
| Goldlust, B | 1 |
| Major, J | 1 |
| Hepburn, B | 1 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Kaspari, S | 2 |
| Kupcinskas, L | 1 |
| Heinze, H | 1 |
| Berghöfer, P | 4 |
| Dekkers, CP | 1 |
| Halstead, LA | 1 |
| Adler, J | 1 |
| Remák, E | 1 |
| Brown, RE | 1 |
| Yuen, C | 1 |
| Robinson, A | 1 |
| Matiño, E | 1 |
| Enrique, A | 1 |
| Ademà, JM | 1 |
| Estivill, E | 1 |
| Fabbri, A | 2 |
| Areni, A | 1 |
| Scialpi, C | 1 |
| Zahlane, D | 1 |
| Geevasinga, N | 1 |
| Coleman, PL | 1 |
| Webster, AC | 1 |
| Roger, SD | 1 |
| Tolia, V | 1 |
| Bishop, PR | 1 |
| Gremse, D | 1 |
| Soffer, EF | 2 |
| Gunaratnam, NT | 1 |
| Jessup, TP | 1 |
| Inadomi, J | 1 |
| Lascewski, DP | 1 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| de Souza Cury, M | 1 |
| Ferrari, AP | 1 |
| Ciconelli, R | 1 |
| Ferraz, MB | 1 |
| Garcia, I | 1 |
| Krishna, P | 1 |
| Rosen, CA | 1 |
| Pratha, V | 3 |
| Hogan, DL | 1 |
| Lynn, RB | 1 |
| Field, B | 1 |
| Eryuksel, E | 1 |
| Dogan, M | 1 |
| Golabi, P | 1 |
| Sehitoglu, MA | 1 |
| Celikel, T | 1 |
| Wo, JM | 1 |
| Koopman, J | 1 |
| Harrell, SP | 1 |
| Parker, K | 1 |
| Winstead, W | 1 |
| Lentsch, E | 1 |
| Book, L | 1 |
| Hammo, AH | 1 |
| Brørs, O | 1 |
| Pai, VG | 1 |
| Pai, NV | 1 |
| Thacker, HP | 1 |
| Shinde, JK | 1 |
| Mandora, VP | 1 |
| Erram, SS | 1 |
| Vcev, A | 1 |
| Begić, I | 1 |
| Ostojić, R | 1 |
| Jurcić, D | 1 |
| Bozić, D | 1 |
| Soldo, I | 1 |
| Gmajnić, R | 1 |
| Kondza, G | 1 |
| Khaznadar, E | 1 |
| Mićunović, N | 1 |
| Glatzel, D | 2 |
| Abdel-Qader, M | 2 |
| Warrington, S | 1 |
| Baisley, K | 1 |
| Lee, D | 1 |
| Lomax, K | 1 |
| Boyce, M | 1 |
| Morocutti, A | 1 |
| Benamouzig, R | 1 |
| Spaniol, U | 1 |
| Kaechele, V | 1 |
| Teutsch, I | 1 |
| Stanghellini, V | 3 |
| Bethke, TD | 1 |
| Achim, A | 1 |
| Riddermann, T | 1 |
| Hogan, D | 1 |
| Riff, D | 1 |
| Ducker, S | 1 |
| Schwartz, H | 1 |
| Soffer, E | 1 |
| Wykypiel, H | 2 |
| Hugl, B | 1 |
| Gadenstaetter, M | 3 |
| Bonatti, H | 1 |
| Bodner, J | 1 |
| Wetscher, GJ | 3 |
| Galmiche, JP | 1 |
| Pai, V | 1 |
| Pai, N | 1 |
| Pérez-Manauta, J | 1 |
| Pakhomova, IG | 1 |
| Bardou, M | 2 |
| Martin, J | 1 |
| Backlund, A | 1 |
| Eckerwall, G | 1 |
| Fjellman, M | 1 |
| Gionchetti, P | 1 |
| Rizzello, F | 1 |
| Straforini, G | 1 |
| Brugnera, R | 1 |
| Liberali, S | 1 |
| Mouly, S | 1 |
| Charlemagne, A | 1 |
| Le Jeunne, P | 1 |
| Fagnani, F | 1 |
| Bader, JP | 1 |
| Delchier, JC | 1 |
| Fitton, A | 1 |
| Wiseman, L | 1 |
| Berstad, A | 1 |
| Chiocca, JC | 1 |
| Salis, GB | 1 |
| Hetzel, D | 1 |
| Mössner, J | 1 |
| Koop, H | 1 |
| Porst, H | 1 |
| Wübbolding, H | 1 |
| Schneider, A | 2 |
| Maier, C | 1 |
| Jaspersen, D | 1 |
| Diehl, KL | 1 |
| Schoeppner, H | 1 |
| Geyer, P | 1 |
| Martens, E | 1 |
| Glaser, K | 1 |
| Profanter, C | 2 |
| Hinder, RA | 1 |
| Kromer, W | 1 |
| Horbach, S | 1 |
| Martin, P | 1 |
| Paul, J | 1 |
| Maton, PN | 1 |
| Lew, E | 1 |
| Pisegna, JR | 2 |
| van Zyl, JH | 1 |
| de K Grundling, H | 1 |
| van Rensburg, CJ | 2 |
| Retief, FJ | 1 |
| O'Keefe, SJ | 1 |
| Theron, I | 1 |
| Bethke, T | 1 |
| Lindbichler, F | 1 |
| Raith, J | 1 |
| Plein, K | 1 |
| Hotz, J | 1 |
| Wurzer, H | 1 |
| Avner, DL | 1 |
| Jungnickel, PW | 1 |
| Humphries, TJ | 1 |
| Biedermann, A | 1 |
| Mey, J | 1 |
| Poole, P | 1 |
| Tytgat, GN | 1 |
| Caro, JJ | 1 |
| Salas, M | 1 |
| Ward, A | 1 |
| Netzer, P | 1 |
| Gut, A | 1 |
| Brundler, R | 1 |
| Gaia, C | 1 |
| Halter, F | 1 |
| Inauen, W | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Klingler, PJ | 1 |
| Weiss, H | 1 |
| Obrist, P | 1 |
| Klaus, A | 1 |
| Hamdan, AL | 1 |
| Sharara, AI | 1 |
| Younes, A | 1 |
| Fuleihan, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children and Adolescents[NCT02186652] | Phase 1 | 41 participants (Actual) | Interventional | 2014-06-04 | Completed | ||
| The Effect of Obesity on the Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD[NCT01887743] | Phase 1 | 71 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD[NCT00325676] | Phase 4 | 639 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, P[NCT01132638] | Phase 3 | 713 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks[NCT00312806] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2006-05-31 | Completed | ||
| A Study for Measurement of Gastric Secretion by Magnetic Resonance Imaging (MRI) Under Inhibition of Gastric Secretion by Proton Pump Inhibitors in Healthy Subjects and Patients With Reflux Disease[NCT01212614] | 24 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis[NCT01733810] | 12 participants (Actual) | Interventional | 2013-02-01 | Completed | |||
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn[NCT00237367] | Phase 4 | 52 participants (Actual) | Interventional | Completed | |||
| Study of a Dietary Supplement for Reflux During Sleep[NCT02274636] | 50 participants (Anticipated) | Interventional | 2014-10-31 | Not yet recruiting | |||
| A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD[NCT00410592] | Phase 4 | 90 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Diseas[NCT00300755] | Phase 3 | 60 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD[NCT00141817] | Phase 3 | 41 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Multicenter, Randomized, Open Label, Single and Multiple Dose Study of the Pharmacokinetics and Pharmacodynamics of 2 Dose Levels of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged 1 Through 11 Months With Presumed GERD[NCT00259012] | Phase 3 | 67 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| Efficacy and Safety of Thread Embedding Acupuncture Combined With PPI in Treating GERD[NCT05353933] | 66 participants (Actual) | Interventional | 2022-05-04 | Completed | |||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report AUC LBW. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | mcg*h/mL (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 5.73 |
| Pantoprazole 12-17 Year Old | 6.82 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report AUC TBW. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | mcg*h/mL (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 8.87 |
| Pantoprazole 12-17 Year Old | 11.56 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report CL/F TBW. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | l/h/kg TBW (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 0.14 |
| Pantoprazole 12-17 Year Old | 0.10 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report Cmax. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | mcg/ml (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 4.27 |
| Pantoprazole 12-17 Year Old | 4.1 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report Tmax. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | hours (Median) |
|---|---|
| Pantoprazole 6-11 Year Old | 2.3 |
| Pantoprazole 12-17 Year Old | 2.5 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report Vd/F LBW. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | L/kg LBW (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 0.25 |
| Pantoprazole 12-17 Year Old | 0.25 |
The pharmacokinetic blood samples will be 1.0 ml each and collected at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours after receiving one dose of Pantoprazole study drug. For those subjects with the poor metabolizer CYP2C19 genotype, an additional PK sample will be obtained at 12 hours after dosing. Here we report Vd/F TBW. (NCT02186652)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, & 8 hours
| Intervention | L/kg TBW (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 0.16 |
| Pantoprazole 12-17 Year Old | 0.14 |
Total number of fresh plasma samples (all participants) (NCT02186652)
Timeframe: Pre-dose (within 30 minutes), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (±10 minutes) after dosing
| Intervention | Plasma samples (Mean) |
|---|---|
| Pantoprazole 6-11 Year Old | 11 |
| Pantoprazole 12-17 Year Old | 11 |
To examine the association of CYP2C19 genotype and its association with CYP2C19 phenotypes. To characterize the ability of the CYP2C19 genotype to predict pantoprazole plasma clearance, a correlation with CYP2C19 phenotype was explored using both standard linear and nonlinear regression techniques and their respective tests for significance and goodness of fit. In addition, the impact of all covariates on pantoprazole systemic exposure and apparent plasma clearance (e.g., demographic determinants of extent of obesity such as the waist:hip ratio, CYP2C19 genotype, BMI, and REE) was explored using validated population-based PK methods (NONMEM). (NCT02186652)
Timeframe: 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose
| Intervention | L/h (Median) |
|---|---|
| *2*2 Allele | 1.29 |
| *1/*2 Allele | 6.00 |
| *1/*1 Allele or *1/*17 Allele | 8.97 |
Concentration of panto in plasma and concentration of panto sulfone in plasma (NCT02186652)
Timeframe: Pre-dose (within 30 minutes), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours (±10 minutes) after dosing
| Intervention | ng/ml (Mean) | |
|---|---|---|
| Pantoprazole | Pantoprazole Sulfone | |
| Pantoprazole 12-17 Year Old | 1626.1 | 88.7 |
| Pantoprazole 6-11 Year Old | 1558 | 94.7 |
Pantoprazole apparent oral drug clearance (CL/F) adjusted for weight for children with the most common CYP2C19 genotypes (i.e., *1/1, *1/17, *1/2, *2/17). Only children with evaluable plasma samples (i.e., at least 85% of planned plasma samples collected) were included in this analysis (n=57). (NCT01887743)
Timeframe: 8 hours
| Intervention | L/hr/kg (Mean) |
|---|---|
| Normal Weight | 0.42 |
| Overweight | 0.29 |
| Obese | 0.23 |
Pantoprazole apparent oral drug clearance (CL/F), not adjusted for weight, for children with the most common CYP2C19 genotypes (i.e., *1/1, *1/17, *1/2, *2/17). Only children with evaluable plasma samples (i.e., at least 85% of planned plasma samples collected) were included in this analysis (n=57). (NCT01887743)
Timeframe: 8 hours
| Intervention | L/hr (Mean) |
|---|---|
| Normal Weight | 20.4 |
| Overweight | 18.7 |
| Obese | 16.8 |
Children with common CYP2C19 genotypes (*1/*1, *1*17, *1/*2, *2/*17) who had evaluable breath test data (n=59) were included to evaluate the breath test's precision in discriminating the CYP2C19 Extensive Metabolizer (EM; *1/*1, *1*17) from the Intermediate Metabolizer (IM; *1/*2, *2/*17) phenotype in the first 3 hrs after study drug administration. A 3-hour window was chosen for convenience. A predictive model using breath test features (change in ratio of C12-to-C13 in exhaled CO2) was build and validated to predictphenotype for each child. We drew bootstrap samples, each stratified to preserve the observed prevalence of EM/IMs in the original cohort (n=59). Sampling with replacement left out 38% of the original sample to use as a test dataset to validate model performance. For each bootstrap sample, a 500-tree Extremely randomized Extra-Tree Forest was constructed after seeding. Using phenotypes predicted by the forest, predictive accuracy was assessed by computing the F1. (NCT01887743)
Timeframe: 3 hours
| Intervention | percent mean predictive performance (Mean) | ||||
|---|---|---|---|---|---|
| 30 minutes | 60 minutes | 90 minutes | 120 minutes | 180 minutes | |
| Breath Test | 81.9 | 84.7 | 83.8 | 84.3 | 82.8 |
Children with common CYP2C19 genotypes (*1/*1, *1*17, *1/*2, *2/*17) who had evaluable breath test data (n=59) were included to evaluate the breath test's precision in discriminating the CYP2C19 Extensive Metabolizer (EM; *1/*1, *1*17) from the Intermediate Metabolizer (IM; *1/*2, *2/*17) phenotype in the first 3 hrs after study drug administration. A 3-hour window was chosen for convenience. A predictive model using breath test features (change in ratio of C12-to-C13 in exhaled CO2) was build and validated to predictphenotype for each child. We drew bootstrap samples, each stratified to preserve the observed prevalence of EM/IMs in the original cohort (n=59). Sampling with replacement left out 38% of the original sample to use as a test dataset to validate model performance. For each bootstrap sample, a 500-tree Extremely randomized Extra-Tree Forest was constructed after seeding. Using phenotypes predicted by the forest, predictive accuracy was assessed by computing precision. (NCT01887743)
Timeframe: 3 hours
| Intervention | percent true EM in total EM predicted (Mean) | ||||
|---|---|---|---|---|---|
| 30 minutes | 60 minutes | 90 minutes | 120 minutes | 180 minutes | |
| Breath Test | 77.3 | 77.7 | 77.3 | 77.8 | 76.9 |
Children with common CYP2C19 genotypes (*1/*1, *1*17, *1/*2, *2/*17) who had evaluable breath test data (n=59) were included to evaluate the breath test's precision in discriminating the CYP2C19 Extensive Metabolizer (EM; *1/*1, *1*17) from the Intermediate Metabolizer (IM; *1/*2, *2/*17) phenotype in the first 3 hrs after study drug administration. A 3-hour window was chosen for convenience. A predictive model using breath test features (change in ratio of C12-to-C13 in exhaled CO2) was build and validated to predictphenotype for each child. We drew bootstrap samples, each stratified to preserve the observed prevalence of EM/IMs in the original cohort (n=59). Sampling with replacement left out 38% of the original sample to use as a test dataset to validate model performance. For each bootstrap sample, a 500-tree Extremely randomized Extra-Tree Forest was constructed after seeding. Using phenotypes predicted by the forest, predictive accuracy was assessed by computing recall. (NCT01887743)
Timeframe: 3 hours
| Intervention | percent identified EM out of total EM (Mean) | ||||
|---|---|---|---|---|---|
| 30 minutes | 60 minutes | 90 minutes | 120 minutes | 180 minutes | |
| Breath Test | 87.8 | 93.6 | 92.3 | 92.4 | 90.2 |
Healed EE was defined as a modified Hetzel-Dent (HD) score <2 on endoscopy at end of study. HD is a standardized rating scale for grading esophageal damage and severity of gastroesophageal reflux disease (GERD). HD score ranges from 0 (normal mucosa) to 4 (deep peptic ulceration). (NCT00300755)
Timeframe: 8 weeks
| Intervention | patients (Number) |
|---|---|
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | 0 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 2 |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | 2 |
Selected symptoms of GERD were assessed using a parent-administered questionnaire. The score for each symptom ranged from 0 (no symptom) to 3 (highest frequency of symptom), The weekly mean score was the sum of daily scores that week, divided by the number of days with scores for that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||
|---|---|---|---|---|---|
| Vomiting/regurgitation | Choking/gagging | Refusal to eat | Difficulty swallowing | Abdominal/belly pain | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | -0.25 | -0.47 | -0.26 | -0.39 | -0.28 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | -0.77 | -0.43 | -0.34 | -0.42 | -0.42 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | -0.06 | -0.05 | -0.16 | -0.13 | -0.24 |
Individual respiratory symptoms weekly score was calculated as the average score / number of events for a patient in the corresponding week if the patient answered a question ≥3 times that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Presence of cold or fever: scale 1=yes 0=no | Cough without cold: scale 1=yes 0=no | Noisy breathing: scale 0(none)-3(most of the time) | Noisy breathing on exhale: scale 1=yes 0=no | Wheezing or whistling sound: scale 1=yes 0=no | Noisy breathing on inhale: scale 1=yes 0=no | Croupy or barky sound: scale 1=yes 0=no | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | 0.11 | -0.24 | -0.16 | -0.16 | -0.02 | -0.16 | -0.13 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | 0.11 | -0.38 | -0.48 | -0.11 | -0.15 | -0.11 | -0.09 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 0.13 | -0.20 | -0.19 | -0.15 | -0.04 | -0.16 | -0.03 |
WGSS is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final week was defined as the last 7 days of symptom scores collected in the treatment period. (NCT00300755)
Timeframe: Baseline and 8 weeks
| Intervention | units on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 1 Change from Baseline | Week 2 Change from Baseline | Week 3 Change from Baseline | Week 4 Change from Baseline | Week 5 Change from Baseline | Week 6 Change from Baseline | Week 7 Change from Baseline | Week 8 Change from Baseline | Final Week Change from Baseline | |
| High Dose Pantoprazole (Approximately 1.2 mg/kg) | -0.47 | -1.24 | -1.38 | -1.32 | -1.30 | -1.42 | -1.58 | -1.61 | -1.66 |
| Low Dose Pantoprazole (Approximately 0.3 mg/kg) | -0.89 | -1.11 | -1.31 | -1.84 | -2.05 | -1.99 | -2.44 | -2.34 | -2.37 |
| Medium Dose Pantoprazole (Approximately 0.6 mg/kg) | 0.02 | -0.11 | -0.16 | -0.20 | -0.48 | -0.61 | -0.58 | -0.60 | -0.64 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | liter per hour per kilogram (L/h/kg) (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 2.08 |
| Pantoprazole 1.2 mg/kg Spheroids | 1.28 |
| Pantoprazole 0.6 mg/kg Tablets | 0.41 |
| Pantoprazole 1.2 mg/kg Tablets | 0.40 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). (NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | ng*h/mL (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 293.29 |
| Pantoprazole 1.2 mg/kg Spheroids | 2448.08 |
| Pantoprazole 0.6 mg/kg Tablets | 2497.13 |
| Pantoprazole 1.2 mg/kg Tablets | 3782.49 |
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t). (NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | nanogram hour per milliliter (ng*h/mL) (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 208.96 |
| Pantoprazole 1.2 mg/kg Spheroids | 2273.96 |
| Pantoprazole 0.6 mg/kg Tablets | 2448.61 |
| Pantoprazole 1.2 mg/kg Tablets | 3190.96 |
(NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | nanogram per milliliter (ng/mL) (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 136 |
| Pantoprazole 1.2 mg/kg Spheroids | 798 |
| Pantoprazole 0.6 mg/kg Tablets | 1643 |
| Pantoprazole 1.2 mg/kg Tablets | 2067 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | hours (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 5.34 |
| Pantoprazole 1.2 mg/kg Spheroids | 1.68 |
| Pantoprazole 0.6 mg/kg Tablets | 0.77 |
| Pantoprazole 1.2 mg/kg Tablets | 0.70 |
Vz/F was calculated as the ratio of clearance (CL) to terminal disposition rate constant (λz). (NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | liter per kilogram (L/kg) (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 12.22 |
| Pantoprazole 1.2 mg/kg Spheroids | 2.89 |
| Pantoprazole 0.6 mg/kg Tablets | 0.43 |
| Pantoprazole 1.2 mg/kg Tablets | 0.40 |
(NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
| Intervention | hours (Mean) |
|---|---|
| Pantoprazole 0.6 mg/kg Spheroids | 1.45 |
| Pantoprazole 1.2 mg/kg Spheroids | 2.71 |
| Pantoprazole 0.6 mg/kg Tablets | 2.08 |
| Pantoprazole 1.2 mg/kg Tablets | 2.03 |
(NCT00141817)
Timeframe: Hours 2 and 4 on Day 7
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Hour 2 on Day 7 (n=5, 8, 10, 13) | Hour 4 on Day 7 (n=6, 8, 10, 13) | |
| Pantoprazole 0.6 mg/kg Spheroids | 212.30 | 503.25 |
| Pantoprazole 0.6 mg/kg Tablets | 592.32 | 123.83 |
| Pantoprazole 1.2 mg/kg Spheroids | 486.49 | 207.23 |
| Pantoprazole 1.2 mg/kg Tablets | 2337.89 | 200.78 |
Pharmacokinetic (PK) parameters, including apparent oral clearance, were determined following a single oral dose of pantoprazole. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. (NCT00259012)
Timeframe: 1 day
| Intervention | L/hr/kg (Mean) |
|---|---|
| Low Dose Pantoprazole (0.6 mg/kg) | 1.54 |
| High Dose Pantoprazole (1.2 mg/kg) | 0.87 |
Pharmacokinetic (PK) parameters, including AUC, were determined following a single oral dose of pantoprazole. AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. (NCT00259012)
Timeframe: 1 day
| Intervention | ng*hr/mL (Mean) |
|---|---|
| Low Dose Pantoprazole (0.6 mg/kg) | 1046 |
| High Dose Pantoprazole (1.2 mg/kg) | 3602 |
Pharmacokinetic (PK) parameters, including the terminal-phase disposition half-life, were determined following a single oral dose of pantoprazole. Half-life is the time required for half the quantity of absorbed drug to be metabolized or eliminated by normal biological processes. (NCT00259012)
Timeframe: 1 day
| Intervention | hr (Mean) |
|---|---|
| Low Dose Pantoprazole (0.6 mg/kg) | 1.78 |
| High Dose Pantoprazole (1.2 mg/kg) | 1.42 |
Pharmacokinetic (PK) parameters, including peak plasma concentration, were determined following a single oral dose of pantoprazole (NCT00259012)
Timeframe: 1 day
| Intervention | ng/mL (Mean) |
|---|---|
| Low Dose Pantoprazole (0.6 mg/kg) | 567 |
| High Dose Pantoprazole (1.2 mg/kg) | 1527 |
Pharmacokinetic (PK) parameters, including time to peak plasma concentration, were determined following a single oral dose of pantoprazole. (NCT00259012)
Timeframe: 1 day
| Intervention | hr (Median) |
|---|---|
| Low Dose Pantoprazole (0.6 mg/kg) | 1.03 |
| High Dose Pantoprazole (1.2 mg/kg) | 1.02 |
Intragastric pH is a method for evaluating gastric acidity scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | units on scale (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 3.0 | 4.2 |
| Low Dose Pantoprazole (0.6 mg/kg) | 4.2 | 4.8 |
Intraesophagel pH is a method for evaluating acidity of gastric refluxate scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | units on scale (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 5.2 | 4.9 |
| Low Dose Pantoprazole (0.6 mg/kg) | 5.7 | 5.6 |
Intraesophagel pH is a method for evaluating acidity of gastric refluxate scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | units on scale (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 5.3 | 4.9 |
| Low Dose Pantoprazole (0.6 mg/kg) | 5.8 | 5.6 |
Intragastric pH is a method for evaluating gastric acidity scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | units on scale (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 2.8 | 4.2 |
| Low Dose Pantoprazole (0.6 mg/kg) | 4.2 | 4.7 |
Normalized Area of Esophageal Hydrogen Ion Activity Over Time is a measure of the area under the curve of the esophageal hydrogen ion activity over time, which is normalized for a 24-hour period. (NCT00259012)
Timeframe: 7 days
| Intervention | H*mmol/L (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 3.5 | 1.5 |
| Low Dose Pantoprazole (0.6 mg/kg) | 2.1 | 1.5 |
Normalized Area of Gastric Hydrogen Ion Activity Over Time is a measure of the area under the curve of the gastric hydrogen ion activity over time, which is normalized for a 24-hour period. (NCT00259012)
Timeframe: 7 days
| Intervention | H*mmol/L (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 921.0 | 303.6 |
| Low Dose Pantoprazole (0.6 mg/kg) | 259.7 | 102.3 |
Plasma concentration of pantoprazole after multiple doses was measured to see if there was any accumulation of the drug. (NCT00259012)
Timeframe: 7 days
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 2 hours | 4 hours | |
| High Dose Pantoprazole (1.2 mg/kg) | 668 | 353 |
| Low Dose Pantoprazole (0.6 mg/kg) | 289 | 69 |
Intragastric pH is a method for evaluating gastric acidity. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | percentage of time (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 32.2 | 56.6 |
| Low Dose Pantoprazole (0.6 mg/kg) | 55.5 | 68.5 |
Intraesophagel pH is a method for evaluating acidity of gastric refluxate. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH <4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD). (NCT00259012)
Timeframe: 7 days
| Intervention | percentage of time (Mean) | |
|---|---|---|
| Baseline | Steady state | |
| High Dose Pantoprazole (1.2 mg/kg) | 8.0 | 9.4 |
| Low Dose Pantoprazole (0.6 mg/kg) | 4.6 | 4.6 |
48 reviews available for pantoprazole and Esophageal Reflux
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazol | 2023 |
Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflu | 2016 |
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi | 2017 |
Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Gastroesophageal R | 2007 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Pantoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Drug Thera | 2010 |
Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Child; Child, Preschool; Cross-Ove | 2011 |
The clinical importance of proton pump inhibitor pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost Savings; Duodenal U | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, | 2002 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; E | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; | 2003 |
[Treatment of reflux disease. An international consensus conference put things in its place].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2003 |
The basis of differentiation of PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Cysteine; Dose- | 2004 |
Understanding NSAID-PPI-COX-2 interrelationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Esomep | 2005 |
Role of pantoprazole in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Gastric Acid; Gastroesophageal Reflux; H(+) | 2005 |
Understanding GERD symptoms in the clinical setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
Extraesophageal manifestations of GERD: diagnosis and therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; | 2005 |
Intravenous proton pump inhibitor therapy: a rationale for use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
The complete remission concept.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagoscopy; Gastroesophageal Reflux; | 2006 |
[Dosaging of proton pumps inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2006 |
The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Databases, Factual; Esomeprazole; Gastro | 2007 |
Long-term management of GERD in the elderly with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; P | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; O | 2007 |
Pantoprazole: from drug metabolism to clinical relevance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Gastroesophage | 2008 |
Clinical efficacy of pantoprazole compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1994 |
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1996 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidon | 1996 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Hu | 1997 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Clinical experience with pantoprazole in gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2000 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
Switching between intravenous and oral pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Cl | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2001 |
Shortcomings of the first-generation proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Biological Availability; Cytochrome P-450 E | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
88 trials available for pantoprazole and Esophageal Reflux
| Article | Year |
|---|---|
A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Double-Blind Method; Drug Therapy, Combination; Female; | 2020 |
Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Aged; Artemisia; Double-Blind Method; Drug Therapy, Combination; Endoscopy, Digestive System; | 2020 |
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.
Topics: Administration, Oral; Adolescent; Area Under Curve; Body Weight; Child; Cytochrome P-450 CYP2C19; Dr | 2018 |
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
Topics: Adolescent; Body Weight; Child; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Female; Follow-U | 2019 |
On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2013 |
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastro | 2013 |
Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2014 |
Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; | 2014 |
Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anxiety; Asian People; Depression; Female; Gastroeso | 2014 |
Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Dietary Supple | 2015 |
Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cross-Over Studies; Double-Blind Method; | 2015 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double | 2016 |
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon R | 2016 |
Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Arousal; Cross-Over Studies; Disorders o | 2008 |
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Cross-Over Studies | 2009 |
Origin of and therapeutic approach to cardiac syndrome X: results of the proton pump inhibitor therapy for angina-like lingering pain trial (PITFALL trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chest Pain; Coronary Angiography; Double-Blind Method | 2008 |
[Using sunpraz in GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Female; Ga | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Body Mass Index; Dose-Response Relationship, D | 2010 |
Effect of pantoprazole in patients with chronic laryngitis and pharyngitis related to gastroesophageal reflux disease: clinical, proximal, and distal pH monitoring results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Chronic Disease; Esophageal pH Monitorin | 2010 |
Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2010 |
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Age Factors; Anti-Ulcer Agents; Aryl | 2010 |
Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Dosage Forms; Double-Blind Method; Dr | 2010 |
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Canada; Child; Child, Preschool; Delayed-Action Pre | 2010 |
Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female | 2011 |
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Child; Delayed-Action Preparations; Dose-Respon | 2011 |
[Pharmacokinetics of the proton pump inhibitors and psychological status in patients as factors that influence the efficiency of treatment of GERD with pantoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Attitude to Health; Female; Gastroesophageal Reflux; | 2010 |
Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anxiety; Body Mass Index; Female; Gastroesophageal R | 2011 |
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Age Factors; Area Under Curve; Child, | 2011 |
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Age Factors; Area Under Curve; Child, | 2011 |
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Age Factors; Area Under Curve; Child, | 2011 |
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Age Factors; Area Under Curve; Child, | 2011 |
Proton-pump inhibitors in sleep-related breathing disorders: clinical response and predictive factors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Esophageal pH Monitoring; Female; Gastroesopha | 2011 |
Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Female; Follo | 2011 |
Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Comorbidity; Esophagitis; Female; | 2011 |
[Efficacy of sequential therapy with pantoprazole in gastro esophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Drug Administration Schedule; Female; | 2011 |
Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dyspepsia; Female; Gastroesophageal Reflux; Humans; | 2012 |
Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; He | 2013 |
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2002 |
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Fol | 2002 |
Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Confidence Intervals; Do | 2003 |
Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Canada; Dou | 2003 |
Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cross-Over | 2003 |
Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studie | 2003 |
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2003 |
Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-S | 2003 |
40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2004 |
Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2004 |
Prevention of erosive oesophagitis relapse with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2004 |
Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2005 |
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; End | 2005 |
Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 2005 |
Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anthropometry; Anti-Ulcer Agents; | 2005 |
On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Female; Gastro | 2005 |
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Dru | 2005 |
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; | 2006 |
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aluminum Hydroxide; Analysis o | 2006 |
Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Rel | 2006 |
Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aluminum Hydroxide; Antacids; Anti-Ulcer Agents | 2006 |
Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2006 |
Esomeprazole versus pantoprazole for healing erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Fema | 2006 |
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Cross-Over Studies; Dose | 2006 |
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2007 |
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Adminis | 2007 |
Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Re | 2007 |
International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Administration Schedule; Esophagoscopy; Female; | 2007 |
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Confidence Intervals; Cross-Over Studies; Dose | 2007 |
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Dose-Response Relationship | 2007 |
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2007 |
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Analysis of | 2007 |
[Use of pantoprazol for treatment of gastroesophageal reflux disease and NSAID-induced gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Ster | 2007 |
Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response | 2008 |
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; | 2008 |
One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz | 1997 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2000 |
Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2000 |
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Dose-Respon | 2000 |
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Do | 2000 |
Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Benzimidazoles; Dose-Response | 2001 |
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cisapride; Double-Blind Method; Drug Therap | 2001 |
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
108 other studies available for pantoprazole and Esophageal Reflux
| Article | Year |
|---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
[Esophagoprotective therapy in patients with erosive esophagitis].
Topics: Antacids; Chondroitin Sulfates; Esophagitis; Gastroesophageal Reflux; Humans; Hyaluronic Acid; Panto | 2022 |
Topics: Gastroesophageal Reflux; Humans; Pantoprazole; Proton Pump Inhibitors | 2019 |
Combined therapy of gabapentin with pantoprazole exhibited better protective action against forestomach and pylorus ligation-induced gastric esophageal reflux disease in albino Wistar rats.
Topics: Afferent Pathways; Animals; Disease Models, Animal; Drug Therapy, Combination; Gabapentin; Gastric E | 2020 |
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study.
Topics: Aged; Alkaline Phosphatase; Anti-Ulcer Agents; Aspartate Aminotransferases; Bacillus; Clostridiales; | 2020 |
Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Citalopram; Drug Therapy, Combination; Electric | 2017 |
Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alanine; Animals; Anti-Ulcer Agents; Disease Models, Animal | 2018 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female | 2018 |
Acute generalized exanthematous pustulosis caused by pantoprazole.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflu | 2018 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; H | 2013 |
Commentary: daily pantoprazole vs. esomeprazole for GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male | 2014 |
Commentary: daily pantoprazole vs. esomeprazole for GERD--authors' reply.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Male | 2014 |
Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electric Impedance; Esomeprazole; Esophageal pH Monitoring; | 2014 |
[Lupus erythematosus and proto-pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Autoantibodies; Biopsy; Diagnosis, Differential; Eso | 2014 |
Pantoprazole may improve beta cell function and diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; | 2014 |
[What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Cohort Studies; Diagnosis, Differential; Esopha | 2014 |
Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Electric Impedance; Esophageal pH Monitoring; | 2014 |
Effect of monotherapy and combination therapy of pantoprazole and aprepitant in gastric esophageal reflux disease in albino rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Aprepitant; Catalase; Disease Models, Animal; Drug | 2014 |
[Comparison of the effectiveness of omeprazole and pantoprazole treatment of gastroesophageal reflux disease in patients with asthma].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Asthma; Female; | 2013 |
Effect of lycopene against gastroesophageal reflux disease in experimental animals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antioxidants; Carotenoids; Catalase; Esophagitis; | 2015 |
[Detection of cytochrome P4502C19 gene polymorphism to optimize therapy of acid-dependent diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Cytochrome P-450 Enzyme System; Female; | 2015 |
[Diagnosis and treatment of vocal process granuloma induced by gastroesophageal reflux: four cases report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Arytenoid Cartilage; Gastroesophageal Reflux; Granuloma; Hu | 2015 |
Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Eosinophils; Esophagitis, Peptic; Esophagus; Female | 2016 |
Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Drug Administration | 2009 |
[Analysis of actual costs in long-term therapy of reflux disease. Use of pantoprazole counts].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Costs and Cost Analysis; Drugs, Generic; | 2008 |
[Efficacy of pantoprazole in the therapy of esophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Drug Adm | 2008 |
International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esophagitis; Female; Gastro | 2009 |
Esophageal cell proliferation in gastroesophageal reflux disease: clinical-morphological data before and after pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Endoscopy; E | 2009 |
Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Comorbidity; Duodenogastric | 2009 |
[Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Gastric Aci | 2008 |
[Antisecretory potential of pantoprasole (sanpraz)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastric Acid; Gastric Acidity Determination; Gastroesophage | 2008 |
[Therapy of gastric acid-induced illnesses in general practice. The first pantoprazole generic drug has arrived].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Cost-Benefit An | 2009 |
[Taking metabolic pathways into consideration. Approved drug against problematic interactions ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogr | 2009 |
The impact of normalization of esophageal acid profile by incremental protein pump inhibitors dosing in difficult asthma patients with proven gastro-esophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Asthma; Dose-Response Relationship, Drug; Esop | 2009 |
[Why some proton pump inhibitors are more equal than others].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Deglutition Disorders; Drugs, Generic; Female; Gastroesopha | 2009 |
Gastro-oesophageal reflux disease in an obese patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastroesoph | 2009 |
Severe gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophageal Diseases; Female; Gastroesoph | 2009 |
Chronic cough--about a clinical case...
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chronic Disease; Cough; Esophagitis, Pep | 2009 |
Pantoprazole available without a prescription: new status. Better than H2 receptor agonists, but not for pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Clinical Trials as Topic; Cont | 2009 |
Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Aging; Aryl Hydrocarbon H | 2011 |
[Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Pantopr | 2010 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
Pantoprazole for symptoms of infant GERD: the emperor has no clothes!
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; P | 2010 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; H | 2010 |
[Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alcoholism; Anorexia; Anti-Inflammatory Agents | 2011 |
Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Esophagogastric Junction; Female; G | 2011 |
Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angiotensins; Animals; Carbachol; Electric Stimulation; Eso | 2011 |
[Panum (pantoprazole) effectiveness in the treatment of patients with GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Algorithms; Esophagitis, Peptic; F | 2011 |
In vitro effect of pantoprazole on lower esophageal sphincter tone in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Carbachol; Cholinergic Agonists; Esophageal Sphinc | 2011 |
Oral pantoprazole-induced acute pancreatitis in an 11-year-old child.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Child; Gastroesophageal Reflux; Human | 2012 |
[Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Humans; Lansoprazol | 2012 |
Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esomeprazole; Esophagitis, Peptic; Female; Gastroeso | 2012 |
Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Bile Reflux; Drug Resistance; Esophageal pH Monitori | 2012 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Canad | 2002 |
Severe esophagitis healed in less than a week with intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Fema | 2003 |
[Pantoprazole-induced hepatitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdomen; Abdominal Pain; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Adverse reactions to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anaphylaxis; Benzimidazoles; Enzyme Inhibitors; Fema | 2003 |
[References for reflux therapy. Preventing nocturnal acid recurrence].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronotherapy; Delayed-A | 2003 |
Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Utilization; Enzyme Inhibitors; Formul | 2003 |
Asthma-like syndrome in a teenager.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Albuterol; Amoxicillin; Androstadienes; Anti-Ba | 2003 |
Acute interstitial nephritis due to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Benzimidazoles; | 2004 |
[Efficacy of controloc in the treatment of acid-dependent diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 2003 |
pH probe positioning for 24-hour pH-metry by manometry or pH step-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Enzyme Inhibitors; Female; Gas | 2004 |
[When sour does not make merry at all . Fast relief for patients with reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
[Stubborn reflux pain, inconspicuous esophagus. Which therapy brings the fastest relief?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
[Graded therapy in reflux disease. "In severe cases 40 mg., in milder 20 mg."].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
GERD 2003: issues from the past and a consensus for the future.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 2004 |
Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Arousal; Benzimidazoles; Circadia | 2004 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
Recurrent anaphylaxis linked to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2004 |
[Attention! Cough, asthma and Co. are often caused by reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Clinical | 2004 |
[Paradigm change in reflux disease. In reflux patients listening to is often more important than endoscopy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
A randomized controlled trial of equivalence between pantoprazole and esomeprazole that does not have the power to conclude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesop | 2005 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
[Basic principles of successful GERD (gastroesophageal reflux disease) therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Balanced perspective essential in erosive oesophagitis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesop | 2005 |
[Gastroesophageal reflux and obstructive sleep apnea syndrome].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Female; Gastroesophageal Reflux; Hum | 2005 |
Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Female; F | 2005 |
[Reflux therapy in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal R | 2005 |
Proton pump inhibitors and acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Adult; Age Distribution; Aged; Aged, 8 | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibi | 2006 |
Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Brazil; Endosco | 2006 |
Severe laryngeal hyperkeratosis secondaryto laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Therapy, Combination; Gastroesophageal | 2006 |
Treatment of laryngopharyngeal reflux improves asthma symptoms in asthmatics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Asthma; Benzimidazoles; Combined | 2006 |
[Reflux-associated nutcracker oesophagus in a 49-year-old patient with non-cardiac chest pain (NCCP)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chest Pain; Esophageal Motility Disorder | 2007 |
Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dose-Response Relationship, Drug; Drug Adminis | 2007 |
Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, | 2007 |
Laparoscopic partial posterior (Toupet) fundoplication improves esophageal bolus propagation on scintigraphy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Esophageal Sphincter, Lowe | 2008 |
EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2008 |
EMANCIPATE versus EXPO: different results can be explained by differing study designs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Omepraz | 2008 |
[Decreased need for tablets with pantoprazole. PPI: independent study questions savings through use of generic drugs].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost Savings; Dose-Response Relationship | 2007 |
[Focus on multi-morbidity patients. Considering the greatest measure of therapy safety].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Comorbidity; Drug Interactions; Drug The | 2007 |
[Drug treatment and surgical indications in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Fundoplication | 2007 |
Oral impact of gastro-oesophageal reflux disease: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Apraxias; Cerebral Palsy; Feeding Behavior | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomepra | 2008 |
Management of Acid-Related Diseases: Focus on Pantoprazole. Proceedings of the 1st International Symposium on Pantoprazole. Berlin, Germany, 1 May 1993.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastroe | 1994 |
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride; | 1999 |
Ex juvantibus approach for chronic posterior laryngitis: results of short-term pantoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; | 1999 |
Pantoprazole (Protonix).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Dose-Response Rel | 2000 |
Treatment strategies for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Intera | 2000 |
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimid | 2001 |
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 2001 |
Pantoprazole IV (Protonix IV).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fe | 2002 |